Diabetes in pregnancy is associated with risks to the woman and to the developing fetus. Miscarriage, pre‑eclampsia and preterm labour are more common in women with pre‑existing diabetes. In addition, diabetic retinopathy can worsen rapidly during pregnancy. Stillbirth, congenital malformations, macrosomia, birth injury, perinatal mortality and postnatal adaptation problems (such as hypoglycaemia) are more common in babies born to women with pre‑existing diabetes.
Diabetes in pregnancy: management from preconception to the postnatal period | Guidance | NICE - gives comprehensive advice on management (1).
All women with diabetes of childbearing age should be counselled on the importance of optimising treatment of their diabetes.
Patient information
Referral
Gestational Diabetes - Risk assessment, testing and diagnosis | Guidance | NICE
Risk Factors
Risk of gestational diabetes in a healthy population include:
Testing
Do not use fasting or random plasma glucose, HbA1c, or urinalysis to assess the risk of developing gestational diabetes.
An oral glucose tolerance test should be performed if there are risk factors or gestational diabetes is suspected (see NG3 for advice on glycosuria and dianostic thresholds)..
Referral
Refer as below if gestational diabetes is confirmed.
Patients with exisiting diabetes who become pregnant or those who develop gestational diabetes should be referred to their local antenatal clinic or diabetes service as appropriate. Referrals can often be done by their community midwife.
(1) Diabetes in pregnancy: management from preconception to the postnatal period | Guidance | NICE
Efforts are made to ensure the accuracy and agreement of these guidelines, including any content uploaded, referred to or linked to from the system. However, BNSSG ICB cannot guarantee this. This guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer, in accordance with the mental capacity act, and informed by the summary of product characteristics of any drugs they are considering. Practitioners are required to perform their duties in accordance with the law and their regulators and nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.
Information provided through Remedy is continually updated so please be aware any printed copies may quickly become out of date.